We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
The most recent trading session ended with Moderna (MRNA - Free Report) standing at $57.73, reflecting a -0.96% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 0.77%. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq saw an increase of 0.87%.
Heading into today, shares of the biotechnology company had lost 14.63% over the past month, lagging the Medical sector's loss of 3% and the S&P 500's gain of 4.87% in that time.
The investment community will be closely monitoring the performance of Moderna in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be -$1.84, reflecting a 32.37% decrease from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $1.27 billion, showing a 30.6% drop compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$9.85 per share and a revenue of $3.2 billion, indicating changes of +20.11% and -53.23%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Moderna. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.31% lower. Moderna is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 86, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
The most recent trading session ended with Moderna (MRNA - Free Report) standing at $57.73, reflecting a -0.96% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 0.77%. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq saw an increase of 0.87%.
Heading into today, shares of the biotechnology company had lost 14.63% over the past month, lagging the Medical sector's loss of 3% and the S&P 500's gain of 4.87% in that time.
The investment community will be closely monitoring the performance of Moderna in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be -$1.84, reflecting a 32.37% decrease from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $1.27 billion, showing a 30.6% drop compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$9.85 per share and a revenue of $3.2 billion, indicating changes of +20.11% and -53.23%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Moderna. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.31% lower. Moderna is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 86, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.